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Ectopic expression of Cdc6p results in mitotic delay, and this has been attributed to Cdc6p-mediated
inhibition of Cdc28 protein kinase and failure to activate the anaphase-promoting complex (APC). Here we
show that endogenous Cdc6p delays a specific subset of mitotic events and that Cdc28 inhibition is not
sufficient to account for it. The depletion of Cdc6p in G2/M cells reveals that Cdc6p is rate limiting for the
degradation of the APC/Cdc20 substrates Pds1p and Clb2p. Conversely, the premature expression of Cdc6p
delays the degradation of APC/Cdc20 substrates. Abolishing Cdc6p/Cdc28p interaction does not eliminate the
Cdc6-dependent delay of these anaphase events. To identify additional Cdc6-mediated, APC-inhibitory mech-
anisms, we looked for mutants that reversed the mitotic delay. The deletion of SWE1, RAD24, MAD2, or BUB2
had no effect. However, disrupting CDC55, a PP2A regulatory subunit, suppressed the Cdc6p-dependent delay
of Pds1 and Clb2 destruction. A specific role for CDC55 was supported by demonstrating that the lethality of
Cdc6 ectopic expression in a cdc16-264mutant is suppressed by the deletion of CDC55, that endogenous Cdc6p
coimmunoprecipitates with the Cdc55 and Tpd3 subunits of PP2A, that Cdc6p/Cdc55p/Tpd3 interaction occurs
only during mitosis, and that Cdc6 affects PP2A-Cdc55 activity during anaphase. This demonstrates that the
levels and timing of accumulation of Cdc6p in mitosis are appropriate for mediating the modulation of
APC/Cdc20.
In order to maintain genomic stability, cells must coordinate
DNA replication such that every origin of replication fires once
and only once per cell cycle (28, 69). The assembly of prerep-
licative complexes (pre-RCs) at origins of replication during
G1 is therefore a tightly regulated process. In Saccharomyces
cerevisiae, the main cyclin-dependent kinase (CDK), Cdc28p,
promotes the initiation of DNA replication at the G1/S tran-
sition and also inhibits aberrant reinitiation by preventing the
assembly of new pre-RCs before each of the progeny cells has
its own complete genome (14, 15, 19, 41).
One of the components of the pre-RC is the Cdc6 protein
(10, 13, 59). Both CDC6 transcription and protein levels are
tightly regulated during the cell cycle. Cdc6 transcription oc-
curs primarily in late M/early G1, but a second independently
controlled wave of transcription has also been observed in late
G1 (37, 45, 73, 74). The MCB box is responsible for CDC6
transcription in late G1, and the ECB box is responsible for the
peak of CDC6 mRNA in late M/G1, 60 to 70 min after -factor
release, when 80% of the cells have metaphase or anaphase
spindles (46). The ECB box is the primary regulator of CDC6
transcription in rapidly dividing cells, and it is also responsible
for the timely expression of other genes involved in mitosis,
such as CDC20 or SPO12, whose mRNA levels peak simulta-
neously with those of CDC6, and also for the replication genes
MCM2 to MCM7 (46). In addition to transcriptional regula-
tion, the levels of the Cdc6 protein are very accurately con-
trolled by cell cycle-dependent proteolysis (16, 20, 43, 45, 52)
and cellular localization (44). There is a peak of protein pro-
duction in late M/early G1, and the protein is very stable during
G1, when it accumulates to high levels in nuclei, but it becomes
very unstable after the G1/S transition. It is also more evenly
distributed between the nucleus and cytoplasm. Cdc6p con-
tains several consensus CDK phosphorylation sites, and the
phosphorylation of Cdc6p by Cdc28p is important for proteol-
ysis, although this dependence varies with the phase of the cell
cycle (7, 17, 20, 43).
The existence of distinctive active Cdc6p degradation mech-
anisms in S phase versus that in mitosis, where the rate of
transcription and protein levels of Cdc6 are already very low,
suggests that the regulation of Cdc6p is still necessary after the
initiation of replication and that, as a consequence, Cdc6p
might play a role in addition to its function in the initiation of
replication.
In this study, in order to better understand the roles of
Cdc6p during the cell cycle, we depleted Cdc6p from cells that
had gone through complete DNA replication and observed a
faster rate of Pds1p and Clb2p degradation in mitosis, suggest-
ing a role of Cdc6p in modulating the activity of anaphase-
promoting complex (APC)/Cdc20 in anaphase. We also ob-
served that Cdc6 expressed under the control of its own
promoter accumulates in mitosis to levels similar to those
obtained by expression from the GAL1,10 promoter. Previous
work showed that the overexpression of a dominant-negative
Cdc6 mutant resulted in a delay of mitosis and that this cor-
related with the inhibition of Cdc28 protein kinase (43), which
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is required for the activation of APC/Cdc20. Although this
previous data suggests that endogenous Cdc6p could affect
APC/Cdc20 by inhibiting Cdc28 protein kinase activity, our
results suggest that there is an additional Cdc6-mediated
mechanism. We find that the expression of two Cdc6 phosphor-
ylation site mutants interferes with the APC by a mechanism
that requires neither interaction with nor inhibition of Cdc28p
or the activation of mitotic checkpoints. The second pathway
of APC inhibition may involve PP2A phosphatase, since the
mitotic delay induced by mutant Cdc6 proteins can be reversed
by the disruption of the CDC55 gene, a regulatory subunit of
PP2A. In agreement with this hypothesis, we show that Cdc6p
interacts with Cdc55p. In addition, the downregulation of
PP2A-Cdc55, which occurs in normal cells, is not observed in
cells devoid of Cdc6 in mitosis. We discuss a model that relates
these results to the regulation of the APC by Cdc6 in a normal
cell cycle.
MATERIALS AND METHODS
Strains and media. Strains were derived from W303 (mata ura3 trp1 leu2 his3
ade2), with the exception of strains expressing hemagglutinin (HA)-tagged
Cdc28p, which were derived from strain RJD635 (mata ura3 leu2 trp1 pep4::TRP1
cdc28::CDC28-HA-HIS3 bar1::LEU2), kindly provided by Ray Deshaies, Califor-
nia Institute of Technology, Pasadena, CA. A complete strain list with the
relevant genotype is available upon request. Strain names used in individual
experiments are provided in the figure legends.
W303 or RJD635 strains expressing myc-tagged Cdc6p under the GAL1,10
promoter were obtained by integrative transformation using previously described
plasmids (20). swe1, cdc55, and Clb2-HA-, p86/91-HA-, and Cdc55-HA-
tagged strains were obtained by the PCR gene replacement method using the
plasmids pFA6a-His3MX6, pFA6a-3HA-His3MX6, and pFA6a-kanMX6 (36).
PDS1-HA strains were obtained by transformation with a PDS1(HA)3::TRP1
fragment from plasmid pSB56, a plasmid derived from pOC52 (kindly provided
by D. Koshland, Carnegie Institution, Baltimore, MD) by replacing the URA3
marker with the TRP1 marker. The disruption of the MIH1 gene was carried out
by transformation with a mih1::LEU2 fragment from plasmid p119 (provided by
P. Russell, Scripps Institute, La Jolla, CA). Gene-disrupted strains were detected
by their specific phenotypes and/or PCR. Epitope-tagged strains were identified
by Western blotting.
Strains with CDC6 under the control of the MET promoter (K4055; mata leu2
his3 ade2 GAL cdc6::hisG trp1::TRP1-MET-CDC6) were obtained from Kim
Nasmyth and further modified by tagging the chromosomal copies of several
genes as described above. CDC6 and mutant CDC6 expressed under its own
promoter and myc tagged at the C terminus were introduced by transformation
with a CEN plasmid or an empty vector.
Cells were routinely grown in 2% glucose selective media, YPRaf (2% raffi-
nose) and YPRaf-Gal (2% raffinose plus 2% galactose) or yeast extract-peptone-
dextrose (2% glucose). Cell plating dilution assays were carried out on selective
plates containing raffinose plus either 2% galactose or 0.02% galactose, obtain-
ing identical results (not shown). For experiments involving liquid cultures of
cdc55 strains, YPSuc (2% sucrose) was used instead of YPRaf, since the latter
does not support the growth of these strains.
Plasmids. Plasmids expressing wild-type Cdc6 and Cdc6 phosphorylation site
mutants under the control of the GAL promoter have been described previously
(21). CDK phosphorylation sites were substituted for alanines as follows: CDC6
A-C (T7A, T23A, and S43A), CDC6 F (S372A), CDC6 EF (S354A, T356A,
T370A, T371A, and S372A), CDC6 A-CF (T7A, T23A, S43A, T370A, T371A,
and S372A), and CDC6 A-F (T7A, T23A, S43A, and S372A). CDC6 N lacks the
N-terminal amino acids 8 to 48. To express CDC6 and mutant CDC6 under
the control of its own promoter, a cassette containing myc-tagged CDC6 and the
CDC6 terminator was excised from the GAL plasmids and cloned in a CEN
vector containing the CDC6 promoter. To construct plasmids expressing C-
terminally deleted Cdc6, we obtained PCR fragments encompassing CDC6 from
residue 1 to residue 401, 428, or 494 and having BamHI and SpeI restriction sites
at their 5 and 3 ends, respectively. These PCR fragments were cloned into the
BamHI-SpeI sites of plasmids derived from pRS306 and pRS315 containing the
GAL1,10 and the CDC6 promoters, respectively, and eight myc tags.
Cell cycle experiments. Early-exponential-phase cells were incubated with 10
g/ml -factor for 2.5 h. To release cells from the arrest, cells were harvested and
washed once with twice the volume of supernatant and released in twice the
original volume of fresh medium. For each time point, 2 ml of the culture was
sampled; 1 ml was processed for flow cytometry, and the other was processed for
immunoblotting as described previously (20). Samples were electrophoresed on
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), trans-
ferred onto Hybond ECL membrane (Amersham) using a semidry transfer
system (Bio-Rad), and blocked with 5% dry milk. Before detection with anti-
bodies, all membranes were routinely stained with Ponceau S to check for equal
loading and transfer. The detection of myc-tagged Cdc6 was performed using the
monoclonal antibody 9E10, and for the detection of HA-tagged proteins, we
used the monoclonal 12CA5 antibody. We used the enhanced chemilumines-
cence reagents according to manufacturer’s instructions. All experiments were
performed at least two times with results equivalent to those presented. The
staining of microtubules was performed as described previously (18) using rat
anti-tubulin antibody (clone YOL1/34). Fluorescence images were collected us-
ing a Carl Zeiss Axiophot FL microscope with a 63 objective and an Olympus
DP70 camera. At least 200 cells were counted for each time point.
Immunoprecipitation and PP2A-Cdc55 phosphatase assay. Yeast extracts
were prepared as described previously (20), except that the resuspension buffer
was 150 mM NaCl and phosphatase inhibitors (50 mM NaF, 5 mM Na4P2O7, and
0.1 mM Na3VO4) were included. A total of 2 mg of protein for strains expressing
wild-type Cdc6p or an empty vector was typically incubated in the resuspension
buffer in a final volume of 0.25 ml with 20 g of the appropriate antibody. In
experiments involving extracts from cells expressing endogenous Cdc6p, we used
5 mg of total extract. After 1 h at 4°C with rotation, 100 l of a 50% slurry of
protein A-Sepharose was added and incubated for one more hour at 4°C with
rotation. Immunoprecipitates were washed six times in the same buffer (four
times with the same buffer and two times with the same buffer but with 250 mM
NaCl to immunoprecipitate Cdc55p) and released from protein A by boiling for
10 min in 1 SDS-PAGE loading buffer. Samples were subjected to SDS-PAGE
and transferred to ECL membranes, and proteins were detected with the 12CA5
(for HA-tagged proteins), 9E10 (for Cdc6-myc), or Tpd3 antibody as described
above.
For phosphatase assays, protein extracts from strains having a chromosomal
copy of CDC55-HA and either expressing myc-tagged CDC6 from the MET
promoter or carrying an empty vector (YSB393 or YSB534, respectively) were
prepared as described above for immunoprecipitation, except that the extraction
buffer did not contain phosphatase inhibitors. A total of 100 g of protein was
immunoprecipitated with the anti-HA antibody to purify Cdc55-HA, and beads
were washed four times with extraction buffer and two times with phosphatase
buffer (50 mM imidazole, pH 7.2, 0.2 mM EGTA, 0.02% -mercaptoethanol, 0.1
mg/ml bovine serum albumin). The beads were then incubated with 45 l of
phosphatase buffer and 5 l of a specific phosphopeptide, RRA(pT)VA, pro-
vided with a serine/threonine phosphatase assay kit (Promega, Madison, WI).
Reactions were allowed to proceed for 30 min at 30°C and stopped by incubation
on ice. Supernatants were collected, transferred to a 96-well plate, mixed with 50
l of the molybdate dye provided with the kit, and incubated at room temper-
ature for 15 min. The total amount of phosphate was determined by reading the
absorbance at 600 nm of the molybdate-malachite green-phosphate complex
using a Victor3 Wallac spectrofluorometer (PerkinElmer, Inc., Wellesley, MA).
Cdc55 recovered from the beads was quantified by Western blotting using a
Personal FX scanner (Bio-Rad) and used to normalize the PP2Ase enzymatic
activity.
RESULTS
Cdc6 plays a role in mitosis before mitotic exit. We reported
several years ago that the ectopic expression of one Cdc6
phosphorylation site mutant (Cdc6 F) (see Fig. 2A) was lethal
in a cdc16 background, and we suggested that Cdc6p might
inhibit the APC (20). Two major events, the metaphase-to-
anaphase transition and mitotic exit, occur sequentially in mito-
sis (reviewed in references 25, 30, and 72). In the metaphase-to-
anaphase transition, chromatids are aligned and begin to
separate to opposite poles of the cell. This event is triggered by
APC/Cdc20-dependent degradation of the securin protein
Pds1, which serves both as a marker for the onset of mitosis in
our studies as well as a marker for APC/Cdc20 activity (11, 66,
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67). APC/Cdc20 is also involved in the degradation of Clb5p
(54) and in a first round of Clb2p degradation contributing to
an initial decrease in Clb/Cdc28 protein kinase activity (34, 63,
71). The second mitotic event, exit from mitosis, involves the
degradation of Clb2p in an APC/Cdh1-dependent manner (23,
26, 27, 58, 60). The resulting global decrease in Clb/Cdc28
activity finally leads to mitotic exit.
In order to test the hypothesis that Cdc6p affected the APC,
we first analyzed the steady-state level of Cdc6p through a
single cell cycle and compared it to the profile of the two
well-characterized mitotic markers: Pds1p and Clb2p. We con-
structed yeast strains that expressed C-terminally tagged myc-
Cdc6p under the control of its own promoter and that con-
tained a chromosomal copy of Pds1 or Clb2 tagged with HA.
We monitored the levels of myc-Cdc6p, Pds1p-HA, and
Clb2p-HA in cells released from -factor arrest to monitor the
metaphase-to-anaphase transition. We observed a peak of
myc-Cdc6p at 20 min after release, after which the levels de-
creased until around 65 min. Levels again increased, peaking at
80 min after release (Fig. 1A). Interestingly, myc-Cdc6p levels
began to increase at exactly the same time when Pds1p-HA
degradation began to be apparent, about 65 min after release
from -factor and in the presence of high levels of Clb2p-HA.
This pattern of expression of Cdc6 is entirely reproducible in
replicate experiments and is in agreement with other recent
data (2).
The cell cycle profile of Cdc6p levels shown in Fig. 1A
suggests that Cdc6p is present at significant levels at a time
when it could inhibit the APC/Cdc20 form of the APC, i.e.,
when Pds1 levels begin to decline. The timing of peak levels of
Cdc6 is 80 min (Fig. 1A), whereas Pds1 degradation is appar-
ent at 65 min after release, suggesting that APC inhibition
would occur after initial activation of APC/Cdc20 and is more
consistent with Cdc6p contributing to the shutoff of APC/
Cdc20 once it had functioned. According to this hypothesis,
cells that are depleted of Cdc6p in mitosis should show a faster
rate of degradation of APC/Cdc20 substrates compared to cells
normally expressing Cdc6p. In order to test this prediction, we
constructed yeast strains where CDC6 expression was regu-
lated by the repressible MET promoter and that had chromo-
somal copies of Clb5, Pds1, or Clb2 tagged with HA. In addi-
tion, they contained either an additional copy of CDC6 under
its own promoter or an empty vector. We grew these cells in
the absence of methionine to allow growth of the cells with the
empty vector and arrested them with -factor. Cells were re-
leased, and methionine was added to interrupt the expression
of Cdc6 during the ensuing cycle. Notice that methionine was
added not immediately after release, but 30 min later in order
to allow sufficient Cdc6p synthesis from the MET promoter to
support late G1 pre-RC assembly and DNA replication. We
analyzed the levels of Pds1p-HA, Clb2p-HA, and Clb5p-HA in
these cells. As predicted by our model, the time of onset of
Pds1p-HA degradation is the same time in the absence of
Cdc6p as in the presence of Cdc6p. However, in the presence
of Cdc6, the degradation of Pds1p-HA and Clb2p-HA fails to
go to completion (Fig. 1B). This result is verified and extended
in Fig. 2. Since the depletion of Cdc6p allows Pds1p degrada-
tion to go to completion, this suggests for the first time that
endogenous Cdc6p may be rate limiting for that degradation.
Although the presence or absence of Cdc6p did not affect
the rate of degradation of Clb5p-HA, the lack of effect on
Clb5p-HA degradation is easily explained when comparing its
levels with those of myc-Cdc6p. By the time that Cdc6p levels
peak (90 to 100 min after -factor release, under the growth
conditions for Fig. 1B), most of Clb5p-HA has already been
degraded. These results show not only that Cdc6p is expressed
significantly before exit from mitosis (Fig. 1A) but also that it
functions in an earlier step than exit from mitosis (Fig. 1B).
FIG. 1. Steady-state levels of Cdc6p through the cell cycle. (A) Yeast cells with a copy of MET-CDC6 and another copy of myc-tagged CDC6
expressed under its own promoter (YSB75) and containing a chromosomal copy of Pds1-HA (YSB441) or Clb2-HA (YSB407) were grown in
synthetic medium and arrested with -factor. Cells were released in rich medium, and samples were taken at 20 min after release and, from then
on, every 5 min to be processed for immunoblotting. -Factor was readded 60 min after release to prevent entry into a new cell cycle. For a
comparison of levels of Cdc6 expressed from its own promoter with those reached by GAL overexpression, we measured the levels of Cdc6 F in
cells arrested with -factor in YPRaf medium, treated with galactose for 15 min, and released in YPRaf-Gal. Note that four times less protein was loaded
in gels from cells expressing GAL-myc-Cdc6 F than in endogenous myc-Cdc6. (B) Advancement of Pds1 and Clb2 degradation by reduction in Cdc6
levels. Yeast cells with a copy of MET-CDC6 and another copy of myc-tagged CDC6 expressed under its own promoter (YSB75) or an empty vector
(YSB431) and containing a chromosomal copy of Pds1-HA (YSB441 and YSB442), Clb2-HA (YSB407 and YSB408), or Clb5-HA (YSB410 and
YSB411) were grown in synthetic medium without methionine and arrested with -factor. Cells were released in synthetic medium without methionine,
and 30 min after release, methionine was added. At the indicated times, samples were taken to be processed for immunoblotting and flow cytometry.
-Factor was readded 70 min after release to prevent reentry into another cell cycle. Notice that for panel A, cells were released in rich yeast
extract-peptone-dextrose medium and, in panel B, they were released in synthetic medium. Therefore the peak of accumulation of Cdc6p is slightly
delayed in panel B.
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Cdc6p does not appear to inhibit the triggering of mitosis since
Clb5p degradation is normal and the onset of Pds1p degrada-
tion occurs with normal timing. Rather, Cdc6p appears to
downregulate APC/Cdc20 after its execution point.
Cell cycle delay in cells expressing stabilized Cdc6p. In
order to gain more insight into the mechanism by which Cdc6p
could modulate APC/Cdc20 activity, we tested the ability of
different Cdc6p mutants to inhibit APC/Cdc20. There are
abundant data in the literature showing that ectopic expression
of Cdc6p results in mitotic delay (3, 5, 43), and this delay
depends on the time of expression of Cdc6p, but not on the
levels of Cdc6p (5). We reasoned that we could induce the
ectopic expression of Cdc6p and its mutants at the metaphase-
to-anaphase transition by using the GAL1,10 promoter. We
could then monitor the effects on the APC/Cdc20, measured as
a mitotic delay by flow cytometry or by the time of onset and
extent of degradation of Pds1p and Clb2p. To validate our
approach, we wanted to show that, in a situation of ectopic
expression of Cdc6p in metaphase-to-anaphase cells, the levels
of Cdc6p attained were similar to the maximum levels of
FIG. 2. (A) Schematic diagram of Cdc6 protein. Vertical lines represent CDK sites A to F, and the amino acid numbers at the top of the
diagram are given for consensus threonines and serines. (B). Cell cycle delay of cells expressing myc-tagged wild-type and mutant Cdc6p. Cells
growing logarithmically in YPRaf medium were transferred to 2% galactose-containing medium, and samples were taken for flow cytometry
analysis at the indicated times. The strains used were YSB57, empty vector; YSB58, GAL-CDC6; YSB117, GAL-CDC6 A-C; YSB116, GAL-Cdc6
F; YSB60, GAL-CDC6 A-CF; YSB61, GAL-CDC6 A-F; YSB62, GAL-CDC6 N8-48; and YSB196, GAL-CDC6 N8-48F. (C) The degra-
dation of cell cycle-regulated Pds1p and Clb2p is delayed in strains overexpressing Cdc6p. W303 strains expressing either the indicated myc-tagged
mutant Cdc6 proteins from the GAL1,10 promoter or an empty vector and expressing either HA-tagged Pds1p (upper panels) or HA-tagged Clb2p
(lower panels) were grown in YPRaf to early log phase and arrested with -factor. After arrest, Cdc6p expression was induced by the addition of
galactose. Fifteen minutes later, cells were washed and released from the arrest into YPRaf-Gal. Samples were taken at the time of release and
every 10 min thereafter during a 130-min time course to be processed for immunoblotting to detect Pds1-HA and Clb2-HA. The Pds1-HA strains
were YSB169, empty vector; YSB170, GAL-CDC6; YSB171, GAL-Cdc6 F; YSB306, GAL-CDC6 A-CF; YSB307, GAL-CDC6 A-F; and
YSB308, GAL-CDC6 N8-48. The Clb2-HA strains were YSB271, empty vector; YSB272, GAL-CDC6; YSB273, GAL-Cdc6 F; YSB274,
GAL-CDC6 A-CF; YSB275, GAL-CDC6 A-F; and YSB304, GAL-CDC6 N8-48. wt, wild type. (D) Benomyl hypersensitivity of Cdc6
phosphorylation site mutants. W303 strains expressing either the indicated myc-tagged mutant Cdc6 proteins from the GAL1,10 promoter or an
empty vector, described in the legend for panel B, were grown in glucose-containing selective medium to stationary phase, serially diluted 10-fold,
spotted in raffinose (as a control) and raffinose plus galactose plates containing 5 g/ml benomyl, and incubated at room temperature for 1 week.
	, absence of; , presence of.
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Cdc6p expressed from its own promoter as shown in Fig. 1A.
To that end, we measured the levels of a stabilized mutant,
myc-Cdc6p F (21). We expressed myc-Cdc6 F from the
GAL1,10 promoter in cells treated with galactose for 15 min
during -factor arrest and released them from the arrest in the
continuous presence of galactose. We observed that at 60 min
after release, i.e., at the metaphase-to-anaphase transition
(Fig. 1A), the levels of myc-Cdc6p F were similar to the peak
of myc-Cdc6p expressed from its own promoter (Fig. 1A, com-
pare the 70-to-80-min time points in the upper panel with the
60-min time point in the lower panel). Similar results compar-
ing the levels of Cdc6p expressed from its own promoter with
those of other stabilized Cdc6 mutant proteins have been de-
scribed in the literature (40). Thus, GAL-induced expression at
metaphase to anaphase is at the same level eventually reached
by wild-type Cdc6p somewhat later in mitosis. This level of
GAL-induced Cdc6p is sufficient to lead to mitotic delay, as we
will show below. These results suggest that expressing Cdc6p
from the GAL1,10 promoter is a valid approach to studying a
physiologically significant mechanism by which the Cdc6p
might downregulate APC/Cdc20 activity.
Cdc6p contains at least six SP or TP motifs that could po-
tentially serve as CDK phosphorylation sites (A to F), three at
the N terminus and three at the C terminus (Fig. 2A). The
mutation of all these sites, a subset of them, or just one site at
the C terminus (Cdc6 F) into unphosphorylatable sites results
in the stabilization of Cdc6p (7, 17, 20, 43). We tested the effect
of expressing these stabilized mutant proteins under the
GAL1,10 promoter on cell growth. Cells containing the endog-
enous CDC6 gene and C-terminal, myc-tagged derivatives of
either wild-type CDC6 or mutant cdc6 under the control of the
GAL1,10 promoter were grown in the presence of galactose for
4 h. Flow cytometry shows that the expression of wild-type
myc-Cdc6p and myc-Cdc6p sites A to C (myc-Cdc6p A-C)
resulted in an accumulation of cells with a 2C content of DNA
after 4 h in galactose (Fig. 2B), suggesting a delay in mitosis, as
previously reported (5, 43). When myc-Cdc6p F, myc-Cdc6p
A-CF, or myc-Cdc6p A-F were expressed, the mitotic delay
was stronger than that in the wild type or Cdc6p A-C since it
was readily observed as early as 2 h after the addition of
galactose and the remaining population of G1 cells was smaller
than that observed for cells expressing wild-type Cdc6p. In
conjunction with this strong mitotic delay, cells had abnormal
cell morphology with hyperpolarized buds (not shown). The
expression of myc-Cdc6p N (lacking the N-terminal amino
acids 8 to 48 containing three Cdk phosphorylation sites [20])
or myc-Cdc6p NF did not have an observable effect on the
cell cycle or on cell morphology. These results suggest that the
N terminus is an important component for the mitotic delay
produced by the expression of C-terminal phosphorylation site
mutants. This result does not contradict the reported effect of
expressing Cdc6 N as the sole source of Cdc6p in the cell, in
which case, Cdc6 N actually caused a significant mitotic delay
(6) since wild-type endogenous Cdc6p is present in our exper-
iments. Furthermore, that work addressed an event in mitotic
exit and we will show below that the dominant phosphorylation
site mutants are monitoring an earlier event.
To further characterize the effect of the different Cdc6p
mutants in mitosis, we monitored the levels of Pds1p-HA and
Clb2p-HA as cells progressed through the cell cycle after a G1
arrest and release. Compared to control cells carrying an
empty vector, where the minimum levels of Pds1p-HA oc-
curred at 90 min after release, cells expressing wild-type myc-
Cdc6p showed a delay of around 10 min in Pds1p-HA degra-
dation and Pds1p-HA levels remained low for a longer time
than those in the control cells (Fig. 2C, upper panel). The
degradation of Clb2p-HA in cells expressing wild-type myc-
Cdc6p was diminished compared to that in control cells.
Clb2p-HA began to decay at about the same time as in cells
with an empty vector, 100 min after release (Fig. 2C, lower
panel), but levels did not continue to decline as they did in the
control. Cells expressing the phosphorylation site mutants
A-CF and A-F showed an even greater delay in Pds1p-HA
degradation than did cells expressing wild-type myc-Cdc6p. In
cells expressing myc-Cdc6p A-CF and myc-Cdc6p A-F, min-
imum levels of Pds1p-HA were not attained until 110 and 120
min after release. These mutations also affected Clb2p-HA
levels, which did not decrease during the entire time course of
the experiment. Cells expressing myc-Cdc6p F showed ex-
tremely slow kinetics of Pds1p degradation, as Pds1p-HA lev-
els did not decrease during the entire time course. In a similar
manner, the levels of Clb2p remained undegraded and con-
stant in cells expressing myc-Cdc6p F. As expected since there
was no cell cycle delay, cells expressing myc-Cdc6p N showed
normal oscillation in the timing of degradation and in the
levels of both Pds1p-HA and Clb2p-HA. The delay and/or
failure in Pds1p and Clb2p degradation indicates that the ex-
pression of Cdc6 phosphorylation site mutants results in a
delay during both the metaphase-to-anaphase transition and
the exit of mitosis. Since Clb2p degradation by the APC/Cdc20
is required for complete Clb2 proteolysis by APC/Cdh1 at the
exit of mitosis, we cannot be certain from our results which
step of the degradation of Clb2 is affected by the Cdc6 protein
(34, 67, 71).
To gain more evidence that Cdc6 ectopic expression was
affecting early mitosis, we tested the ability of cells expressing
phosphorylation site mutants to grow in the presence of sub-
lethal concentrations of the microtubule-depolymerizing drug
benomyl, which triggers the spindle assembly checkpoint and
transient inhibition of APC/Cdc20.
We found that benomyl did not have any effect in cells
expressing wild-type myc-Cdc6p (Fig. 2D). However, it had a
very strong inhibitory effect on the growth of cells expressing
myc-Cdc6p A-CF, myc-Cdc6p A-F, and myc-Cdc6p F. While
the myc-Cdc6p F cells were compromised for growth in even
the absence of benomyl, they are further inhibited by benomyl
and the Cdc6p A-CF and Cdc6p A-F are clearly supersensi-
tive to benomyl. Our interpretation of these results is that
benomyl treatment and ectopic expression of phosphorylation
site mutants have additive effects in the inhibition of the APC/
Cdc20, resulting in a permanent arrest.
Pds1p is a primary target of the cell cycle checkpoint path-
ways that survey DNA integrity and the proper assembly and
orientation of the mitotic spindle (9). Therefore, one possible
explanation for the Pds1p degradation delay in cells expressing
Cdc6p is that ectopic expression of Cdc6p triggers one of these
checkpoints and arrests cells at the metaphase-to-anaphase
transition. To investigate this possibility, we constructed null
strains in genes involved in the DNA damage and spindle
checkpoint pathways and tested whether they could suppress
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the cell cycle defects. We did not observe the suppression of
the delay in Pds1p-HA degradation or the extremely elongated
cell morphology (not shown) in any of the strains tested
(rad24, mad1, and bub2). These results suggest that the
G2/M delay caused by ectopic expression of Cdc6p is not me-
diated by the DNA replication or the spindle checkpoint.
Cdc28 activity in cells expressing different Cdc6p mutants.
The full activation of the APC at the metaphase-to-anaphase
transition requires active Cdc28 protein kinase (49, 50). Since
Cdc6p interacts with Cdc28 protein kinase through the N ter-
minus (7, 21, 44, 64) and very high levels of Cdc6p may inhibit
Cdc28 protein kinase activity (3, 21, 43), we hypothesized that
stable Cdc6p mutants could result in an increased inhibition of
the Cdc28 protein kinase activity and this would result in de-
creased APC activity. Such inhibition has been observed
for another dominant-negative C-terminal mutant, cdc6-d2
(T368M), which maps near to the site F (S372A) used in our
studies (43). In addition, previous work from other groups
showed that the overexpression of wild-type Cdc6p late in the
cell cycle resulted in an accumulation of cells with a 2C content
of DNA (5) and this delay in cell cycle progression was signif-
icantly increased when Cdc6p was expressed in a mih1 back-
ground. Mih1p is a phosphatase that removes an inhibitory
phosphate group at Tyr 19 in Cdc28p and an activator of
Cdc28p (4, 51). Cells lacking MIH1 have compromised Cdc28
activity. We wanted to know whether the disruption of the
MIH1 gene would also have an effect when the Cdc6 phosphor-
ylation site mutants were expressed in the yeast background
used in our studies. Figure 3A shows that the expression of
wild-type myc-Cdc6p in cells defective for the MIH1 gene re-
sults in a clear growth defect, and the expression of the C-
terminal phosphorylation site mutant (myc-Cdc6p EF) re-
sults in lethality. However, the expression of the other
phosphorylation site mutants does not have a greater effect
than that observed in a wild-type background. Interestingly,
the expression of wild-type Cdc6p in a mih1 background
produces the same elongated bud cell morphology observed in
wild-type cells expressing mutant Cdc6p F (not shown).
To study the inhibition of Cdc28p by Cdc6p in more detail,
we looked at the ability of Cdc6 phosphorylation site mutants
to interact with Cdc28p and we performed coimmunoprecipi-
tation assays. We used yeast strains that express Cdc28p tagged
with the HA epitope from its natural promoter and induced
the expression of myc-tagged Cdc6p with galactose. As shown
in Fig. 3B, only wild-type myc-Cdc6p and myc-Cdc6p F were
capable of interacting with endogenous Cdc28p. These are the
same myc-Cdc6 proteins to which mih1 strains are supersen-
sitive, that is, strains with reduced Cdc28 activity (Fig. 3A).
myc-Cdc6p A-C, myc-Cdc6p A-CF, and myc-Cdc6p A-F,
lacking three N-terminal phosphorylation sites, failed to coim-
munoprecipitate with detectable levels of Cdc28p (Fig. 3B).
Similar conclusions about the effects of these mutations on
Cdc6p/Cdc28p interaction have been reached in in vitro stud-
ies using Cdc6 mutant proteins expressed in insect cells (64).
The fact that phosphorylation site mutants were capable of
producing a mitotic delay (Fig. 2) but only those with wild-type
N-terminal sites were capable of binding Cdc28p and were
lethal in a mih1 background is the key evidence that the
inhibitory interaction between Cdc6p with Cdc28p is not the
exclusive mechanism for the mitotic delay.
More evidence was obtained by studying the Pds1p degra-
dation kinetics in cells expressing myc-Cdc6p A-C from its own
promoter and as the only source of Cdc6p (Fig. 3C), rather
than from the GAL1,10 promoter (Fig. 2B). Despite the fact
that this mutant does not interact with Cdc28p, the degra-
dation kinetics of both Pds1p-HA and Clb2p-HA are identical
to those in cells expressing wild-type Cdc6p. These results
suggest that there may be different pathways for the mitotic
delay produced by different phosphorylation site mutants.
To directly analyze Cdc28p activity in vivo, we measured the
phosphorylation state of the B subunit of DNA polymerase 
(p86/91; POL12), an in vivo substrate of the Cdc28 protein
kinase (22). The inhibition of Cdc28p by the overproduction of
Sic1p, a CDK inhibitor, results in the complete inhibition of
the phosphorylation of p86 to p91 in nocodazole-arrested cells
(12, 22). We constructed yeast strains that expressed myc-
tagged CDC6 under the control of the GAL1,10 promoter and
that contained a single chromosomally integrated copy of HA-
tagged POL12. We induced the expression of wild-type or
mutant Cdc6p with galactose in nocodazole-arrested cells. As
expected from results of investigating the overexpression of
cdc6-d2 with a mutation in a nearby amino acid and which
specifically prevents late G2/M degradation of Cdc6p (43),
myc-Cdc6p F had a small inhibitory effect on Cdc28 protein
kinase activity since a band of p86 could be detected (Fig. 3D).
Importantly, the expression of myc-Cdc6p A-CF, which, like
myc-Cdc6p F, results in Pds1p degradation delay and the ac-
cumulation of cells with a 2C content of DNA, did not result in
a detectable inhibition of Cdc28p, as nonphosphorylated p86
was not present. This result indicates that, in nocodazole-ar-
rested cells, only Cdc6 mutants that interact with Cdc28p are
capable of inhibiting it, suggesting either that Cdc6p A-CF
does not inhibit Cdc28p at all or that it inhibits a different form
of Cdc28p than the one present in nocodazole-arrested cells.
More important, this shows that Cdc6 mutants that neither
interact with nor inhibit Cdc28p can nevertheless cause a G2
delay.
As described above, we and others have observed that the
mitotic delay due to Cdc6p ectopic expression in G2 is en-
hanced in a mih1 background. Although, in S. cerevisiae, the
phosphorylation state of Tyr 19 on Cdc28p is not important in
an unperturbed cell cycle (1, 57), it becomes important in
conditions in which the actin cytoskeleton is perturbed (33, 38,
56). Under these conditions, the Swe1 protein kinase phosphor-
ylates Cdc28p at Tyr 19 and the resulting inhibition of Cdc28
protein kinase prevents the entry into mitosis. Dephosphory-
lation by Mih1 phosphatase is then essential for entry into
mitosis. Therefore, it is possible that Cdc28p inhibition by
Cdc6p ectopic expression, if any, results from the stimulation
of inhibitory phosphorylation of Tyr 19 by Swe1 protein kinase.
If so, swe1 yeast strains would be expected to suppress the
mitotic delay due to GAL-induced Cdc6p expression.
To study this possibility, we performed cell cycle kinetic
experiments monitoring the levels of Pds1p-HA in cells ectopi-
cally expressing myc-Cdc6p F in a swe1 background. These
experiments were performed simultaneously with those shown
in Fig. 2C and 4C, where a wild-type, isogenic strain carrying
an empty vector was used as control for normal Pds1 degra-
dation kinetics. swe1 does not suppress the delay of Pds1p
degradation (shown in Fig. 4C so that important controls are in
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the same figure). In addition, swe1 did not suppress the ex-
treme elongated bud morphology of cells expressing myc-
Cdc6p F, myc-Cdc6p A-CF, or myc-Cdc6p A-F (not shown).
However, swe1 did suppress the growth defects and the elon-
gated phenotype of mih1 strains expressing wild-type GAL-
myc-Cdc6p and also the lethality of expressing GAL-myc-
Cdc6p F in a mih1 background (not shown). In summary,
swe1 is able to overcome only the effects of deleting MIH1, as
expected, not those of expressing mutant Cdc6p from the
GAL1,10 promoter.
FIG. 3. (A) Lethality of Cdc6 phosphorylation site mutants in a mih1 background. W303 or isogenic mih1 (W303 mih1) strains expressing
either the indicated myc-tagged mutant Cdc6 proteins from the GAL1,10 promoter or an empty vector were grown in glucose-containing selective
medium to stationary phase, serially diluted 10-fold, spotted in either raffinose (as a control) or raffinose plus galactose selective plates, and
incubated at 30°C for 2 days. The mih1 strains were YSB198, empty vector; YSB199, GAL-CDC6; YSB157, GAL-CDC6 EF; YSB201,
GAL-CDC6 A-CF; YSB202, GAL-CDC6 A-F; and YSB203, GAL-CDC6 N8-48. (B) Interaction between Cdc6p and Cdc28p. Strains (YSB161,
empty vector; YSB162, GAL-CDC6; YSB163, GAL-Cdc6 F; YSB164, GAL-CDC6 A-C; YSB166, GAL-CDC6 A-CF; and YSB167, GAL-CDC6
A-F) containing HA-tagged Cdc28p under the control of its natural promoter and expressing either the indicated myc-tagged mutant Cdc6 proteins
from the GAL1,10 promoter or an empty vector were grown in YPR to mid-log phase, and galactose was added to induce the expression of Cdc6p.
After 2 h, total yeast extracts were prepared and subjected to immunoprecipitation (IP). The top panel corresponds to HA immunoprecipitates
blotted with the 9E10 anti-myc antibody. The bottom panel corresponds to myc immunoprecipitates blotted with the 12CA5 anti-HA antibody.
(C) Yeast cells with a copy of MET-CDC6 and another copy of myc-tagged wild-type CDC6 (YSB75) or CDC6 A-C (YSB133) expressed under
its own promoter and containing a chromosomal copy of Pds1-HA or Clb2-HA were grown in synthetic medium without methionine and arrested
with -factor (the Pds1-HA strains were YSB441 and YSB478, and the Clb2-HA strains were YSB407 and YSB472). The cells were further treated
as described in the legend for Fig. 1B. (D) Effect of wild-type and mutant Cdc6p overexpression on Cdc28 kinase activity. W303 strains (YSB359,
empty vector; YSB360, GAL-CDC6; YSB361, GAL-CDC6 F; and YSB364, GAL-CDC6 A-CF) containing HA-tagged p86/91 and expressing the
indicated forms of myc-tagged Cdc6p under the GAL1,10 promoter were grown to early log phase in YPRaf and arrested with nocodazole (Noc).
After nocodazole arrest, galactose was added for 2.5 h and samples were taken to be processed for Western blotting to detect p86/91. wt, wild type.
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Altogether, these results show that the mitotic delay pro-
duced by ectopic Cdc6p expression might result from Cdc28p
inhibition. However, the mechanism for this inhibition would
be only partially explained by inhibitory interaction with Cdc6p
as not all mutants that show the delay interact with Cdc28p.
This also does not appear to be an effect of Cdc6p on stimu-
lating Swe1-mediated inhibitory phosphorylation of Cdc28p
since swe1 does not reverse the mitotic delay in any mutant.
Thus, there must be an additional, Cdc6-mediated mechanism
of inhibiting the APC/Cdc20.
Suppression of mitotic delay by deletion of CDC55. Since the
activation of APC/Cdc20 involves the phosphorylation of the
APC core subunits (49, 50) and dephosphorylation should oc-
cur to inhibit APC/Cdc20 in the process of shifting to APC/
Cdh1 for exit from mitosis, a role for phosphatases in APC/
Cdc20 regulation is attractive. Actually, a role for PP2A
phosphatase in the inhibition of the APC/Cdc20 has been de-
scribed in Xenopus and clams (32, 55). In addition, there is also
documented genetic and biochemical interaction between
PP2A and the APC (31, 61). In yeast, there are only two
regulatory subunits, Cdc55p and Rts1p. The function of
Cdc55p has been related to the mitotic checkpoint, although
the precise role is controversial (39, 61). Cdc55p has also been
related to Cdc28p phosphorylation by Swe1p because cells dis-
rupted for CDC55 have increased levels of Swe1p (39, 61, 68).
To determine whether PP2A-Cdc55 played a role in the
mitotic delay produced by Cdc6p, we first looked at the cell
cycle profile of cdc55 cells expressing Cdc6 mutants. As
shown in Fig. 4A, the deletion of CDC55 suppressed the mi-
totic cell cycle delay seen in wild-type strains due to expressing
myc-Cdc6p F and myc-Cdc6p A-CF under the GAL1,10 pro-
moter. Flow cytometry showed identical cell cycle distribution
in cdc55 cells expressing an empty vector, wild-type myc-
Cdc6p, or the mutants (Fig. 4A). cdc55 cells had two peaks
corresponding to content of 1C and 2C DNA as opposed to
wild-type W303 cells expressing mutant Cdc6, which showed an
accumulation of 2C DNA, as is also shown in Fig. 2B. To
further confirm that cdc55 suppressed the mitotic delay, we
tested whether the deletion of CDC55 would suppress the
lethality of the expression of the Cdc6 mutants in an APC-
defective background. In fact, cdc55 suppressed the lethality
of expressing all stable Cdc6 phosphorylation site mutants in
FIG. 4. Suppression of mitotic delay. (A) W303 and W303 cdc55 cells expressing the indicated myc-tagged mutant Cdc6 proteins from the
GAL1,10 promoter and growing logarithmically in either YPRaf or YPSuc were transferred to 2% galactose-containing medium, and samples were
taken for flow cytometry analysis at the indicated times. Flow cytometry profiles of normally cycling cultures (asynchronous; no galactose added)
were also obtained. The cdc55 strains were YSB335, empty vector; YSB336, GAL-CDC6; YSB337, GAL-CDC6 F; and YSB340, GAL-CDC6
A-CF. (B) cdc16-264 and cdc16-264 cdc55 strains expressing either the indicated myc-tagged mutant Cdc6 proteins from the GAL1,10 promoter
or an empty vector were grown in glucose-containing selective medium to stationary phase, serially diluted 10-fold, spotted in either glucose (as
a control) or raffinose plus galactose selective plates, and incubated at 30°C for 2 days. The cdc16-264 strains were YSB172, empty vector; YSB173,
GAL-CDC6; YSB176, GAL-CDC6 EF; YSB177, GAL-CDC6 A-CF; YSB178 GAL-CDC6 A-F; and YSB323 GAL-CDC6 N8-48. The
cdc16-264 cdc55 strains were YSB416, empty vector; YSB417, GAL-CDC6; YSB418, GAL-CDC6 EF; YSB419, GAL-CDC6 A-CF; YSB420,
GAL-CDC6 A-F; and YSB421, GAL-CDC6 N8-48. (C) Wild-type (YSB169), cdc55 (strains described in the legend for panel A), and swe1
strains (YSB248) expressing the indicated myc-tagged mutant Cdc6 proteins from the GAL1,10 promoter and expressing HA-tagged Pds1p were
grown to early log phase in YPSuc (cdc55) or YPRaf (swe1) and arrested with -factor. After arrest, Cdc6p expression was induced by the
addition of galactose. Fifteen minutes later, cells were washed and released from the arrest into YPSuc-Gal or YPRaf-Gal. Samples were taken
at the time of release and every 10 min thereafter during a 130-min time course to be processed for immunoblotting.
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the cdc16-264 strain (Fig. 4B). Finally, we compared the kinet-
ics of Pds1p-HA degradation of cdc55 cells expressing Cdc6p
phosphorylation site mutants to the kinetics of degradation in
wild-type strains expressing the same Cdc6 mutants. cdc55
cells containing HA-PDS1 under the control of its natural pro-
moter and myc-CDC6 mutants under the GAL1,10 promoter
were arrested with -factor and released as described in the
legend for Fig. 2C. As described for experiments with the
swe1 strain, these experiments were performed simulta-
neously with those shown in Fig. 2C, where a wild-type isogenic
strain carrying an empty vector was used as control for normal
Pds1 degradation kinetics and where the effects of the Cdc6
mutants in the wild-type (CDC55) background are shown. Fig-
ure 4C shows a return to normal kinetics of Pds1p-HA degra-
dation in the cdc55 strain expressing myc-Cdc6p F, myc-
Cdc6p A-CF, and myc-Cdc6p A-F as opposed to swe1
CDC55 strains expressing myc-Cdc6p F. These results demon-
strate that Cdc55p is involved in the delays caused by ectopic
Cdc6p expression (39, 61, 68).
Cdc6 interacts physically and functionally with Cdc55, but
only during mitosis. To obtain evidence for a direct role for
Cdc6 in Cdc55 activity, we determined whether Cdc6p and
Cdc55p could interact. We HA tagged the chromosomal copy
of CDC55 in cells expressing wild-type and myc-Cdc6 F under
the GAL1,10 promoter and performed coimmunoprecipitation
assays. As shown in Fig. 5A, Cdc55p immunoprecipitated with
both wild-type myc-Cdc6p and myc-Cdc6p F. It also interacted
with other Cdk-phosphorylation site mutants of Cdc6 (not
shown).
To rule out the possibility that the interaction was an artifact
of GAL induction, we performed immunoprecipitation assays
with extracts from cells expressing myc-Cdc6 from its own
promoter. Furthermore, we assessed the interaction at various
points in the cell cycle in cells growing synchronously after
-factor release. We observed a clear, cell cycle-specific inter-
action between myc-Cdc6p and Cdc55p-HA that occurred at
about 80 min after release and was somewhat diminished by 90
min (Fig. 5B). The narrow interval of interaction may explain
why the asynchronous cells used in Fig. 5A showed less Cdc55
in the Cdc6 immunoprecipitates than did the synchronized
cells in Fig. 5B. The interaction occurred when the levels of
myc-Cdc6p were maximum, which is in agreement with our
FIG. 5. (A) Interaction between Cdc6p and Cdc55p. W303 strains expressing HA-tagged Cdc55p (YSB399) and either the indicated myc-tagged
mutant Cdc6p from the GAL1,10 promoter or an empty vector were grown to mid-log phase in YPRaf, galactose was added to induce the
expression of Cdc6p for 3 h, and total extracts were prepared. The top and middle panels represent a fraction (1/500) of the total input material
in the immunoprecipitation (IP) blotted with the anti-myc-Cdc6 (9E10) and anti-Cdc55-HA (12CA5) antibodies, respectively. The bottom panel
represents one-third of the Cdc6-myc immunoprecipitates blotted with the anti-HA antibody 12CA5. The Cdc55-HA strains used were YSB289,
empty vector; YSB290, GAL-CDC6; and YSB291, GAL-CDC6 F. wt, wild type. (B) Cell cycle-specific interaction between Cdc6, Cdc55, and Tpd3.
Yeast cells with a copy of MET-CDC6 and another copy of myc-tagged CDC6 expressed under its own promoter and containing a chromosomal
copy of Cdc55-HA (YSB393) was grown in synthetic medium and arrested with -factor and released in rich medium. Samples were taken, and
total cell extracts were prepared from arrested cells and from cells at the indicated times after release. Cdc6-myc immunoprecipitates prepared
with the 9E10 antibody were blotted and probed with 9E10, 12CA5, and -Tpd3 for Cdc6-myc, Cdc55-HA, and Tpd3, respectively. (C and D)
Cdc55-PP2A activity during the cell cycle in wild-type cells (C) or in cells depleted of Cdc6 in mitosis (D). Yeast cells with a copy of MET-CDC6
and another copy of myc-tagged CDC6 expressed under its own promoter (YSB393) or an empty vector (YSB534) and containing a chromosomal
copy of Cdc55-HA were grown in synthetic medium without methionine and arrested with -factor. They were further treated as described in the
legend for Fig. 1B. Extracts, immunoprecipitations, and phosphatase assays were carried out at the indicated time points. Histograms represent
the mean values and standard errors of three experiments. Immunoprecipitated HA-Cdc55 from both yeast strains that was used to normalize the
phosphatase levels is shown below the graphs. 	, absence of; , presence of.
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hypothesis that Cdc6p is present at sufficient levels to inhibit
APC/Cdc20 after the metaphase-to-anaphase transition. We
also probed the blot carrying proteins immunoprecipitated by
the anti-myc-Cdc6 antibody with an antibody against a struc-
tural subunit of the PP2A, Tpd3p, and we found that Tpd3p
was present in the immunoprecipitate, suggesting that Cdc6p
interacted with the PP2A holoenzyme and not just with the
regulatory subunit Cdc55p (Fig. 5B). We obtained identical
results with a strain where Cdc55 was not tagged (not shown).
The suppression of Cdc6-mediated cell cycle delay in cdc55
mutants and the Cdc6/Cdc55 interaction suggest the possibility
that Cdc6p might affect the kinetics of dephosphorylation or
the ratio of phosphorylation/dephosphorylation of a Cdc55
substrate and, in turn, affect the passage through mitosis. Phos-
phatase PP2A associated with Ccd55p has recently been de-
scribed as a negative regulator of mitosis (62, 70) by preventing
Net1p phosphorylation and Cdc14p nucleolar release (47). We
reasoned that Cdc6p could affect the cell cycle-regulated ac-
tivity of PP2A-Cdc55. To study this possibility, we measured
the Cdc55-associated phosphatase activity in wild-type cells
released from -factor arrest and in cells treated similarly but
deprived of Cdc6p. We observed that PP2A-Cdc55-specific
activity gradually decreased in wild-type cells, reaching 50% of
the initial activity at 80 min after release (Fig. 5C). In contrast,
in cells that proceeded through mitosis without Cdc6p, the
specific activity of PP2A-Cdc55 was maintained at a level sim-
ilar to that observed in G1 phase (Fig. 5D). Note the change in
ordinate scales in the two graphs shown in Fig. 5C and D. As
an independent control for cell cycle progression, we moni-
tored spindle elongation. Long anaphase spindles started to
appear at the same time in both strains, namely, by 70 min after
release, and reached a maximum in both strains at 90 min,
which was in agreement with numerous previous studies (13,
58, 74). This indicates that the reduction in PP2A-Cdc55 ac-
tivity in cells expressing Cdc6 occurred during anaphase and
that the sustained PP2A-Cdc55 activity in cells deprived of
mitotic Cdc6 also occurred during anaphase and was not due to
failure to enter mitosis. The phosphatase assay shows a func-
tional interaction between Cdc6 and PP2A-Cdc55 at the same
point in the cell cycle as where physical interaction is observed.
The functional interaction supports the conclusion that the
physical interaction is physiologically significant (see Discus-
sion).
Ability of Cdc6 mutants to interact with Cdc55 and cause
delay. To gain more insight into the interaction between Cdc6p
and Cdc55p and into its physiological significance, we analyzed
the strength of interactions between Cdc55p and various
Cdc6p deletion mutants. According to crystallographic data
obtained with archaeal Cdc6 and upon alignment of archaeal
Cdc6 with the Schizosaccharomyces pombe Cdc6p ortholog,
Cdc18, Liu and colleagues proposed that Cdc6p is structured
in three domains: the two more N-terminal domains form an
AAA-type nucleotide binding fold, and the third domain, at
the C terminus, adopts a winged-helix fold similar to that of
known DNA binding modules (35). Since domains I and II are
involved in the assembly of pre-RC and the formation of active
replication complexes (42, 53, 65, 48) and since Cdc6p with a
deletion in the amino acids 8 to 48 can still interact with
Cdc55p (not shown), we reasoned that domain III in Cdc6p
could be important for Cdc55p interaction. By alignment of S.
cerevisiae Cdc6p with S. pombe Cdc18, we determined that
domain III in S. cerevisiae encompassed the last 113 amino
acids, from 401 to 513. We constructed yeast strains that ex-
pressed Cdc6p mutants lacking different portions of the C-
terminal domain under the GAL1,10 promoter, and we carried
out Cdc6p/Cdc55p coimmunoprecipitation assays. A series of
mutants was also constructed in which, in addition to various
deletions at the Cdc6p C terminus, the N-terminal domain had
the Cdc28 phosphorylation site mutations A to C. The A to C
mutants failed to interact with Cdc28p. As shown in Fig. 6A,
Cdc55p-HA can interact with myc-Cdc6p lacking amino acids
401 to 513, suggesting that the interaction involves amino ac-
ids 49 to 401. Interestingly, the deletion of the last 20 amino
FIG. 6. (A) Structure/function analysis of the effect of various
Cd6p deletion mutations on the extent of interaction with Cdc55p.
W303 strains expressing HA-tagged Cdc55p (YSB399) and carrying
either an empty vector or vectors expressing the indicated myc-tagged
Cdc6p C-terminal deletion mutant from the GAL1,10 promoter were
grown to mid-log phase in YPRaf, galactose was added to induce the
expression of Cdc6p for 3 h, and total extracts were prepared and
subjected to immunoprecipitation. The top panel corresponds to myc
immunoprecipitates blotted with the 9E10 anti-myc antibody. The
bottom panel corresponds to myc immunoprecipitates blotted with the
12CA5 anti-HA antibody. The Cdc55-HA strains were YSB289, empty
vector; YSB290, GAL-CDC6; YSB423, GAL-CDC6 401-513; YSB424,
GAL-CDC6 428-513; YSB425, GAL-CDC6 494-513; YSB427, GAL-
CDC6 401-513 A-C; YSB428, GAL-CDC6 428-513 A-C; and YSB429,
GAL-CDC6 494-513 A-C. (B) Pds1-HA degradation kinetics in cells
expressing endogenous levels of either wild-type (wt) Cdc6p or differ-
ent Cdc6 deletion mutants, each of which is indicated to the left of
each blot. As a control of nonfunctional Cdc6p, the effect of the
expression of Cdc6 K114E is also included. Yeast cells with a copy of
MET-CDC6 (K4055) and a plasmid-borne copy of the indicated myc-
tagged CDC6 mutant expressed under the control of its own promoter
or an empty vector and also containing a chromosomal copy of
Pds1-HA were subjected to the same experimental conditions as those
described in the legend for Fig. 1B. The strains used were YSB441,
CDC6; YSB442, empty vector; YSB488, CDC6 401-513; YSB490,
494-513; YSB482, 401-513 A-C; YSB483 494-513 A-C; and
YSB479, CDC6 K114E.
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acids (494 to 513) seemed to increase the interaction with
Cdc55p. This effect was especially evident when Cdc6p had the
A to C Cdk site mutations in the N-terminal domain, suggest-
ing a competition between Cdc55p and Cdc28p for binding
Cdc6p. This competition may account for the fact that the
cdc6N mutant binds Cdc55 but does not lead to detectable
attenuation of APC/Cdc20 Pds1 degradation. The results also
show that the last 20 amino acids of Cdc6p (494 to 513) may
have an inhibitory role in the interaction between Cdc6p and
Cdc55p.
We also tested the ability of these Cdc6p mutant proteins to
carry out various Cdc6p functions. When these mutants were
expressed as the only source of Cdc6p, none of them could
support growth (not shown). We next tested the effect of ex-
pressing these C-terminal deletion mutants on the Pds1p deg-
radation in a normal cell cycle. The expression of all C-termi-
nal deletion mutants resulted in a wild-type profile of Pds1p
accumulation and degradation, which was expected, as all of
them could interact with HA-Cdc55p. Mutant Cdc6p401-513
A-C shows an enhanced interaction with HA-Cdc55p but an
identical Pds1-HA degradation profile, suggesting that a lim-
ited quantity of Cdc55-HA interacting with Cdc6 may suffice to
exert a physiological effect.
We have thus found that C-terminal deletion mutants that
interact with Cdc55p have an effect on Pds1p accumulation
which is like that of wild-type Cdc6p. The fact that none of
these mutants can support growth and yet most of them inhibit
the APC to levels similar to those of wild-type Cdc6p indicates
that the faster Pds1p degradation kinetics in cells not express-
ing any source of Cdc6p is not due to lethality effects associ-
ated with the lack of Cdc6p replication function, but rather to
another function in the Cdc6p itself. In a similar manner, the
expression of myc-Cdc6pK114E as the only source of Cdc6p, a
mutant defective in pre-RC formation that does not support
growth (42, 65), also results in normal kinetics of Pds1p deg-
radation (Fig. 6B). This result also suggests that preventing
the assembly of the pre-RC in mitosis is not an essential step
for the role of Cdc6p in modulating mitosis.
DISCUSSION
These studies were initiated in an attempt to explain the
inhibition of mitosis observed by Bueno and Russell (5) due to
the ectopic expression of Cdc6 in G2 phase, but not in other
phases of the cell cycle. A partial explanation for Cdc6-induced
mitotic delay was previously found in the fact that a highly
overproduced Cdc6 mutant protein inhibited Cdc28 activity,
which is needed to activate the APC through phosphorylation
of the Cdc20 subunit. However, it was not clear whether this
was the only mechanism by which Cdc6 inhibited mitosis or
whether it could occur with endogenous levels of Cdc6. There-
fore, we decided to study the effects of various Cdc6 mutants,
particularly but not exclusively those that fail to interact with
Cdc28, to try to identify other, potentially more direct, Cdc6-
mediated mechanisms for modulating the APC (20). Four lines
of evidence support the existence of two Cdc6-dependent mi-
totic inhibitory mechanisms, one dependent on Cdc28 and one
not. First, we previously showed that ectopic expression of one
Cdc6 phosphorylation site mutant (Cdc6 F) was lethal in a
mutant affecting a core subunit of the APC, cdc16. Second,
here we find that the depletion of Cdc6 causes an advancement
of the time of complete degradation of APC substrates. Third,
the manipulation of levels of Cdc6 through GAL induction
causes a delay of complete degradation of two APC substrates,
Pds1 and Clb2, but some Cdc6 mutants that neither interact
with nor inhibit Cdc28 cause even greater delay than does
wild-type Cdc6. Fourth, these latter mutants have an additive
effect on cell viability with benomyl, a drug that leads to the
inhibition of APC/Cdc20.
The Cdc6 depletion experiment seems to confirm that en-
dogenous levels of Cdc6 could inhibit the APC and that the
high levels used in previous studies and required to inhibit
Cdc28 were not essential. The cell cycle expression profile of
Cdc6p (Fig. 1A) and the effect of turning off Cdc6p expression
(Fig. 1B) suggest that Cdc6p would inhibit the APC/Cdc20
after its activation, perhaps contributing to its shutoff once it
had functioned.
One novel observation made during control experiments was
that, unexpectedly, the levels of Cdc6p in late mitosis are at
least as high as those reached upon the induction of the
GAL1,10 promoter (Fig. 1A). This reduced the concern that
effects observed after galactose induction could be artifacts of
overproduction and allowed us to use GAL induction to study
possible Cdc28-independent effects of Cdc6. By flow cytom-
etry, we showed that Cdc6 mutants produce a strong delay of
cells in G2/M and that this cell cycle delay correlates with the
stabilization of Pds1p and Clb2 (Fig. 2C). The stronger effect
of various Cdc6 mutants versus that of the wild type is probably
due to the fact that Cdc6 is an intrinsically unstable protein and
that the mutations we used lead to stabilization (7, 17, 21, 43).
Several further findings suggested that, while Cdc28 inter-
action can contribute to these effects of Cdc6, they cannot
explain the whole cell cycle delay. An indirect argument is that
Pds1 and Clb2 degradation starts at the same time in all situ-
ations, suggesting that there is sufficient Cdc28 to activate the
APC. A more direct argument derives from the difference in
the ability of Cdc6p A-CF and Cdc6p F to inhibit Cdc28p,
which implies the existence of two mechanisms relevant to the
G2/M delay. One involves inhibitory interaction between
Cdc6p and Cdc28p at very high levels of Cdc6p and is repre-
sented by Cdc6p F, which interacts with Cdc28p in vitro and
partially inhibits Cdc28p in nocodazole-arrested cells in vivo
(Fig. 3). The second and new mode of inhibition is highlighted
by Cdc6p A-CF, which does not bind Cdc28p in vitro or
inhibit Cdc28p in vivo detectably (Fig. 3) but nevertheless
extends the half life of APC targets and blocks the cell cycle in
mitosis (Fig. 2 and 4). The Cdc28-independent mechanism
could operate in the presence of lower levels of Cdc6 protein
and would be in agreement with the fact that we observed a
delay in Pds1p degradation very shortly after Cdc6 induction
with galactose, when Cdc6 levels were still quite low and would
not be expected to inhibit Cdc28, and with the fact that we
observed the same growth defects in medium containing either
2% galactose or 0.02% galactose, which induces levels of
Cdc6p expression much lower than 2% (not shown). It may
also be significant that, although we did observe some in vivo
inhibition of Cdc28p by Cdc6p F, the level of inhibition was
much lower than that previously described by others studying
the Cdc6-d2 mutant protein (43). This difference most likely
arises from the fact that Cdc6p F mutants are less stable and do
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not accumulate to levels as high as those of Cdc6-d2 (43). The
presence of active Cdc28p in Cdc6-F mutants demonstrated in
Fig. 3, however, was unexpected, even though the APC seems
to be inhibited, as evidenced by Pds1p stabilization and cell
cycle delay.
Several potential Cdc6-mediated mechanisms that might ex-
plain Cdc6-dependent, Cdc28-independent cell cycle delays
were considered and ruled out. The stabilization of the Sic1p
Clb/Cdc28 repressor was not at work since sic1 does not
reduce Cdc6-induced mitotic delay (43). Stimulating inhibitory
phosphorylation of Cdc28p Tyr 19 by the Swe1 kinase was not
the explanation, since swe1 did not reverse either the inhibi-
tion of Pds1p degradation in cells expressing Cdc6 F (Fig. 4C)
or the morphological defects of the strains expressing other
phosphorylation site mutants. The inhibition of Mih1 seemed
unlikely since the disruption of MIH1 affected only strains
overexpressing wild-type Cdc6 or C-terminal mutants, which,
interestingly, are those that are capable of interacting with
Cdc28p, but not strains expressing other phosphorylation site
mutants (Fig. 3A and B). These data are very similar to pre-
vious reports describing cdc34 sic1 mutants. The disruption
of SWE1 was not capable of rescuing the G2/M arrest of cdc34
sic1 strains grown at the restrictive temperature, whereas
these cell cycle defects were increased in a mih1 background
(29), which is what we see with cell cycle delay during the
expression of stable Cdc6 mutants. Our results are in agree-
ment with this Cdc34 substrate being Cdc6. Cell cycle check-
points were not involved.
Adenovirus E4orf4 protein induces Cdc55-PP2A-dependent
growth arrest in yeast and interacts with the APC. Also, as with
Cdc6, adenovirus protein E4orf4 expression in yeast results in
a mitotic delay increased in a mih1 background but not sup-
pressed by the disruption of SWE1 (31). We therefore inves-
tigated cdc55 mutants defective in a regulatory subunit of
PP2A and found that cdc55 suppresses the Cdc6-mediated
delay of APC substrate destruction, the Cdc6-mediated cell
cycle delay, and the lethality of the overexpression of Cdc6p in
a cdc16 (APC mutant) background (Fig. 4). Normal Pds1 deg-
radation (Fig. 4C) suggests that cdc55 does not just lead to a
bypass of a mitotic exit block related to the inhibition of sepa-
rase, which is required to downregulate Cdc55-phosphatase 2A
activity (47), as a result of the increased levels of Pds1 (se-
curin), a separase inhibitor. Instead, the reversal of Cdc6-
induced APC target stabilization suggests that CDC55 may be
involved at a step prior to the separase-PP2A interaction step
(47). Furthermore, the premature release of Cdc14 into the
nucleus, which might occur in cdc55 cells (47), would not be
expected to enhance Pds1 degradation since Cdc14 is not an
activator of APC-Cdc20. We also do not think that the cdc55
is acting to decrease the inhibition of Cdc28p, since Swe1p
protein kinase levels are increased in cdc55 cells which
should result in increased Cdc28p inhibition (39, 61, 68). Fur-
thermore, Cdc55-PP2A is not the phosphatase involved in re-
moving the activating phosphorylation of Cdc28p at Thr 169
(8). Despite the fact that cdc55 does not suppress the growth
defects of cdc23 or cdc16 strains grown at the restrictive tem-
perature (61), it can suppress the temperature sensitivity of
cdc20-1 mutants (61), maybe by indirectly activating APC/
Cdh1, as suggested by Wang and Ng (62). A more likely pos-
sibility is that ectopic expression of Cdc6p could be leading to
changes in the phosphorylation status of a common substrate
of both Cdc28 and Cdc55 required for APC/Cdc20 activity or
even in the phosphorylation status of the APC/Cdc20 itself.
This could occur by Cdc6 targeting Cdc55-PP2A to this sub-
strate. CDC55 deletion would result in the inability of Cdc6 to
target Cdc55-PP2A to this substrate and thus restore APC/
Cdc20 activity. In other words, Cdc6 may affect a substrate
whose phosphorylation state is kept within a functional range
by an appropriate balance of Cdc28 and Cdc55 activities.
If Cdc6 targets Cdc55 to substrates in mitosis, then we pre-
dict that the two proteins would interact. In fact, we presented
evidence for both physical and functional interaction between
Cdc6 and Cdc55 during mitosis (Fig. 5). Cdc6 and Cdc55
coimmunoprecipitate during mitosis, and Cdc6 has an effect on
PP2A-Cdc55 phosphatase since cells expressing Cdc6 show
downregulation of PP2A-Cdc55 activity in anaphase and cells
lacking Cdc6 show no decrease in PP2A-Cdc55 activity (Fig.
5C and D). The sustained levels of PP2A-Cdc55 activity might
be expected to inhibit mitosis, but this is difficult to sort out
given that the absence of Cdc6 will also lead to an increase in
Cdc28 protein kinase activity. The fact that Cdc6p interacts
with Cdc55p in mitosis but not other parts of the cell cycle and
the fact that, in the absence of Cdc6p, Pds1p degradation is
increased suggest that Cdc6p-Cdc55p interaction should have
an inhibitory effect on the protease activity of the APC. This
APC inhibitory effect might occur in the context of decreasing
levels of Cdc55 phosphatase activity, as our results suggest, by
increased phosphorylation of APC regulators. This might seem
to contradict the observed reduced inhibition of APC in ele-
vated PP2A-Cdc55 in cells lacking Cdc6, but in the absence of
Cdc6, the higher levels of Cdc55 could not be targeted to
mitotic substrates, and as mentioned above, an increase in
Cdc28 protein kinase activity would counteract higher Cdc55
phosphatase activity.
The idea that Cdc6 may play a role in mitosis in addition to
its function as a component of the pre-RC has been repeatedly
proposed since it was shown that the ectopic expression of
wild-type Cdc6 resulted in a delay in the G2/M stage of the cell
cycle (5), and other groups have consistently reported similar
results both for budding and fission yeast (24, 43). In addition
to Cdc6 inhibiting entry into mitosis, Clb/Cdc28 inhibition by
Cdc6 has been implicated in promoting timely exit from the
cell cycle (46, 63, 6, 2). Newly synthesized and stabilized Cdc6,
which is present at significant levels (Fig. 1), could also serve in
a normal cell cycle to fully inhibit APC/Cdc20 before Cdc20
degradation in late mitosis. At this point, Cdc6 could interact
with CDC55-PP2A and perhaps contribute to its downregula-
tion, as results in Fig. 5 suggest. An interesting possibility is
that Cdc28-bound Cdc6 could affect Cdc55 phosphatase activ-
ity. Despite the decrease in Cdc55-PP2A activity, the remain-
ing activity could be targeted to a mitotic substrate that would
then contribute to the deactivation of the APC/Cdc20. Alter-
natively, increased phosphorylation of APC regulators would
result in APC/Cdc20 inhibition. Cdc6-mediated inhibition of
Clb/Cdc28 would provide an additional means to inactivate
APC/Cdc20. In fact, we have observed that Cdc6 N interacts
with Cdc55, but does not interact with Cdc28 and does not
inhibit the cell cycle, suggesting that both Cdc28 inhibition and
Cdc55 inhibition may be required for proper APC regulation.
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